Wang H, Kaur G, Sankin AI, Chen F, Guan F, Zang X. Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies. J Hematol Oncol. 2019;12(1):1–20.

Article  Google Scholar 

Abbasi S, Totmaj MA, Abbasi M, Hajazimian S, Goleij P, Behroozi J, et al. Chimeric antigen receptor T (CAR-T) cells: Novel cell therapy for hematological malignancies. Cancer Med. 2023. https://doi.org/10.1002/cam4.5551.

Article  PubMed  Google Scholar 

Marofi F, Motavalli R, Safonov VA, Thangavelu L, Yumashev AV, Alexander M, et al. CAR T cells in solid tumors: challenges and opportunities. Stem Cell Res Ther. 2021;12(1):1–16.

Article  Google Scholar 

Wen L, Cheng F, Zhou Y, Yin C. MiR-26a enhances the sensitivity of gastric cancer cells to cisplatin by targeting NRAS and E2F2. Saudi J Gastroenterol. 2015;21(5):313.

Article  PubMed  PubMed Central  Google Scholar 

Grosskopf AK, Labanieh L, Klysz DD, Roth GA, Xu P, Adebowale O, et al. Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors. Sci Adv. 2022;8(14):eabn8264.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Machuca-Aguado J, Rodríguez-Zarco E, Carrero-García B, Vázquez-Ramírez FJ. Metastasis of uveal melanoma in bladder: presentation of two cases and review of the literature. Arch Esp Urol. 2022;75(10):873–7.

Article  PubMed  Google Scholar 

Murad JP, Tilakawardane D, Park AK, Lopez LS, Young CA, Gibson J, et al. Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity. Mol Ther. 2021;29(7):2335–49.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang A, Zhou W. Mn-based cGAS-STING activation for tumor therapy. Chin J Cancer Res. 2023;35(1):19.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li M, Wei J, Xue C, Zhou X, Chen S, Zheng L, et al. Dissecting the roles and clinical potential of YY1 in the tumor microenvironment. Front Oncol. 2023;13:1122110.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Park AK, Fong Y, Kim S-I, Yang J, Murad JP, Lu J, et al. Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors. Science translational medicine. 2020;12(559):eaaz1863.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Evgin L, Kottke T, Tonne J, Thompson J, Huff AL, van Vloten J, et al. Oncolytic virus–mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice. Sci Translational Med. 2022;14(640):2231.

Article  Google Scholar 

Ricca JM, Oseledchyk A, Walther T, Liu C, Mangarin L, Merghoub T, et al. Pre-existing immunity to oncolytic virus potentiates its immunotherapeutic efficacy. Mol Ther. 2018;26(4):1008–19.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu Y, Zheng Y, Deng T, Huang Y, Liu Z, Zhan B, et al. Oncolytic herpes simplex virus delivery of dual CAR targets of CD19 and BCMA as well as immunomodulators to enhance therapeutic efficacy in solid tumors combined with CAR T cell therapy. Front Oncol. 2022;12:1037934.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Keshavarz M, Ebrahimzadeh MS, Miri SM, Dianat-Moghadam H, Ghorbanhosseini SS, Mohebbi SR, et al. Oncolytic Newcastle disease virus delivered by Mesenchymal stem cells-engineered system enhances the therapeutic effects altering tumor microenvironment. Virol J. 2020;17(1):1–13.

Google Scholar 

Arina A, Corrales L, Bronte V. Enhancing T cell therapy by overcoming the immunosuppressive tumor microenvironment. Seminars Immunol. 2016. https://doi.org/10.1016/j.smim.2016.01.002.

Article  Google Scholar 

Pan L, Feng F, Wu J, Fan S, Han J, Wang S, et al. Demethylzeylasteral targets lactate by inhibiting histone lactylation to suppress the tumorigenicity of liver cancer stem cells. Pharmacol Res. 2022;181: 106270.

Article  CAS  PubMed  Google Scholar 

He B, Zhang Y, Zhou Z, Wang B, Liang Y, Lang J, et al. A neural network framework for predicting the tissue-of-origin of 15 common cancer types based on RNA-Seq data. Front Bioeng Biotechnol. 2020;8:737.

Article  PubMed  PubMed Central  Google Scholar 

Chen S, Zeng J, Huang L, Peng Y, Yan Z, Zhang A, et al. RNA adenosine modifications related to prognosis and immune infiltration in osteosarcoma. J Transl Med. 2022;20(1):228.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Takamatsu M, Hirata A, Ohtaki H, Hoshi M, Ando T, Ito H, et al. Inhibition of indoleamine 2, 3-dioxygenase 1 expression alters immune response in colon tumor microenvironment in mice. Cancer Sci. 2015;106(8):1008–15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu Z, Wang Y, Zhang L, Huang L. Nanoparticle-delivered transforming growth factor-β siRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment. ACS Nano. 2014;8(4):3636–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sağlam Ö, Ünal ZS, Subaşı C, Ulukaya E, Karaöz E. IL-6 originated from breast cancer tissue-derived mesenchymal stromal cells may contribute to carcinogenesis. Tumor Biology. 2015;36:5667–77.

Article  PubMed  Google Scholar 

Zhao H, Tang S, Tao Q, Ming T, Lei J, Liang Y, et al. Ursolic acid suppresses colorectal cancer by down-regulation of Wnt/β-catenin signaling pathway activity. J Agric Food Chem. 2023;71(9):3981–93.

Article  CAS  PubMed  Google Scholar 

Chang Q-Q, Chen C-Y, Chen Z, Chang S. LncRNA PVT1 promotes proliferation and invasion through enhancing Smad3 expression by sponging miR-140-5p in cervical cancer. Radiol Oncol. 2019;53(4):443.

Article  PubMed  PubMed Central  Google Scholar 

Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, et al. Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci Translational Med. 2013;5(200):200ra116-200ra116.

Article  Google Scholar 

Mao X, Chen Y, Lu X, Jin S, Jiang P, Deng Z, et al. Tissue resident memory T cells are enriched and dysfunctional in effusion of patients with malignant tumor. J Cancer. 2023;14(7):1223.

Article  PubMed  PubMed Central  Google Scholar 

Zhang Y, Xiong X, Huai Y, Dey A, Hossen MN, Roy RV, et al. Gold nanoparticles disrupt tumor microenvironment-endothelial cell cross talk to inhibit angiogenic phenotypes in vitro. Bioconjug Chem. 2019;30(6):1724–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu T, Han C, Wang S, Fang P, Ma Z, Xu L, et al. Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy. J Hematol Oncol. 2019;12(1):1–15.

Article  Google Scholar 

Yonenaga Y, Mori A, Onodera H, Yasuda S, Oe H, Fujimoto A, et al. Absence of smooth muscle actin-positive pericyte coverage of tumor vessels correlates with hematogenous metastasis and prognosis of colorectal cancer patients. Oncology. 2005;69(2):159–66.

Article  PubMed  Google Scholar 

Xu H, Wang H, Zhao W, Fu S, Li Y, Ni W, et al. SUMO1 modification of methyltransferase-like 3 promotes tumor progression via regulating Snail mRNA homeostasis in hepatocellular carcinoma. Theranostics. 2020;10(13):5671.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garbi N, Arnold B, Gordon S, GnJ H, Ganss R. CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J Immunol. 2004;172(10):5861–9.

Article  CAS  PubMed  Google Scholar 

Sakemura R, Cox MJ, Hansen MJ, Hefazi M, Roman CM, Schick KJ, et al. Targeting cancer associated fibroblasts in the bone marrow prevents resistance to chimeric antigen receptor T cell therapy in multiple myeloma. Blood. 2019;134:865.

Article  Google Scholar 

Keshavarz M, Miri SM, Behboudi E, Arjeini Y, Dianat-Moghadam H, Ghaemi A. Oncolytic virus delivery modulated immune responses toward cancer therapy: challenges and perspectives. Int Immunopharmacol. 2022;108: 108882.

Article  CAS  PubMed  Google Scholar 

Jhawar SR, Thandoni A, Bommareddy PK, Hassan S, Kohlhapp FJ, Goyal S, et al. Oncolytic viruses—natural and genetically engineered cancer immunotherapies. Front Oncol. 2017;7:202.

Article  PubMed  PubMed Central  Google Scholar 

Schäfer S, Weibel S, Donat U, Zhang Q, Aguilar RJ, Chen NG, et al. Vaccinia virus-mediated intra-tumoral expression of matrix metalloproteinase 9 enhances oncolysis of PC-3 xenograft tumors. BMC Cancer. 2012;12:1–9.

Article  Google Scholar 

Kleijn A, Kloezeman J, Treffers-Westerlaken E, Fulci G, Leenstra S, Dirven C, et al. The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity. PLoS ONE. 2014;9(5):e97495.

Article  PubMed  PubMed Central  Google Scholar 

Sette P, Amankulor N, Li A, Marzulli M, Leronni D, Zhang M, et al. GBM-targeted oHSV armed with matrix metalloproteinase 9 enhances anti-tumor activity and animal survival. Molecular Therapy-Oncolytics. 2019;15:214–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guedan S, Rojas JJ, Gros A, Mercade E, Cascallo M, Alemany R. Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppres